Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy

Abstract

Letters7 July 2009Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin TherapyBenjamin P. Geisler, MD and Jeffrey K. Levin-Scherz, MD, MBABenjamin P. Geisler, MDFrom Harvard School of Public Health, Boston, MA 02115.Search for more papers by this author and Jeffrey K. Levin-Scherz, MD, MBAFrom Harvard School of Public Health, Boston, MA 02115.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-1-200907070-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We were surprised that Eckman and colleagues (1) found through comprehensive modeling that genotyping before warfarin therapy instead of standard care without genotyping is not cost effective compared with other, well-accepted medical interventions.We suggest that additional factors may improve the cost-effectiveness of warfarin genotyping. For example, if patients with a short-term warfarin indication (that is, uncomplicated deep venous thrombosis) had their genotype recorded in an interoperable electronic health record, this test would not need to be repeated before subsequent warfarin use. Because genotype testing is the largest component of costs, additional benefit would accrue with limited ...Reference1. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73-83. [PMID: 19153410] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Harvard School of Public Health, Boston, MA 02115.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation Mark H. Eckman , Jonathan Rosand , Steven M. Greenberg , and Brian F. Gage Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy Mark H. Eckman , Jonathan Rosand , Steven M. Greenberg , and Brian F. Gage Metrics 7 July 2009Volume 151, Issue 1Page: 71KeywordsConflicts of interestDeep vein thrombosisElderlyElectronic medical recordsFallsGenotypingHemorrhage ePublished: 7 July 2009 Issue Published: 7 July 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...